GSK3B and Alzheimer disease: We found that the levels of TG2 and RhoA phosphorylation at S188 were decreased in AD patients, whereas the level of GSK3β phosphorylation at Y216 was increased (Supplementary Fig. 8a–c), indicating that the TG2-RhoA-ROCK-GSK3β pathway is impaired in AD.